Sacituzumab govitecan (solution)
Product Specifications
Product Name Alternative
IMMU-132 (solution)
UNSPSC Description
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1].
Target Antigen
Antibody-Drug Conjugates (ADCs); TROP2
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related;Immunology/Inflammation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sacituzumab-govitecan-solution.html
Purity
96.61
Solubility
10 mM in DMSO
Smiles
[Sacituzumab govitecan (solution)]
References & Citations
[1]Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31.|[2]Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-132254A/Sacituzumab-govitecan-solution-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-132254A/Sacituzumab-govitecan-solution-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1491917-83-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1391899-01 0.02 mg (E-Coli)
Recombinant Frankia alni Putative sporulation transcription regulator WhiA (whiA)
Ask
View Details